CTLA4 and non-small cell lung carcinoma: For example, ICT, which aims to target molecules highly expressed in tumours, such as PD-L1/PD-1 and CTLA-4, to reduce the depletion of effector T cells [17], is especially effective in SKCM [18] and NSCLC [19].